A CRISPR-based treatment to stop the replication of both the flu virus and the virus that causes COVID-19 in mice. Moreover, the new treatment is delivered to the lungs via a nebulizer, which could make it simple for patients to administer themselves at home.
The treatment uses a type of CRISPR to target viral RNA and appears to stop replication of both viruses in the lungs.
One in 17 people will suffer from a rare disease at some time in their lives. Most of these rare diseases have a genetic cause and often affect children, but proving which gene change causes a disease is a huge challenge.
Scientists have discovered a new genetic disease, which causes some children’s brains to develop abnormally, resulting in delayed intellectual development and often early onset cataracts.
The majority of patients with the condition, which is so new it doesn’t have a name yet, were also microcephalic, a birth defect where a baby’s head is smaller than expected when compared to babies of the same sex and age.
Researchers from the universities of Portsmouth and Southampton found that changes in a gene called coat protein complex 1 (COPB1) caused this rare genetic disease.
Any discussion of rejuvenation biotechnology almost certainly includes the subject of and the objection that medical advances that directly address the various processes of aging will lead to an overpopulated world. Such dire predictions are a common theme in many discussions involving advances in medicine that could increase human lifespans.
Overpopulation is a word that gives the simple fact of population growth a negative connotation. It implies that an increase in the number of people will harm our lives in different ways, such as famine, scarcity of resources, excessive population density, increased risks of infectious diseases, and harm to the environment.
This concern, first raised by the work of 18th century reverend and scholar Thomas Malthus, has been a constant theme in both popular fiction and early foresights related to population growth. However, is it actually well-founded? We will be taking a deeper look at the historical and present population data and showing why is unlikely to happen.
Clip from Lew Later (This iPhone is 1 in 100 Million…) — https://youtu.be/OczdkxrD2uQ.
Oral treatment with a bacterial protein known as colonization factor antigen I (CFA/I) fimbriae, from Escherichia coli bacteria, has been shown to protect against several autoimmune diseases, including arthritis and type 1 diabetes. Another bacteria, called Lactococcus lactis, was recently adapted to express CFA/I fimbriae. These bacteria were shown to effectively suppress inflammation by the induction of regulatory T-cells (Tregs) — which are negative regulators of the immune system, meaning they work to shut down excessive inflammatory responses.
Oral treatment with a molecule produced by bacteria, called colonization factor antigen I, can reduce or halt the progression of Sjögren’s syndrome, a mouse study suggests.
Researchers believe these findings provide the basis for future testing in patients with Sjögren’s.
The study, “Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjögren’s syndrome,” was published in the journal Arthritis Research & Therapy.
New research shows that members of a bee colony all have the same gut microbiome, which controls their smell—and thus their ability to separate family from foe.
This is Scientific American’s 60-Second Science. I’m Shahla Farzan.
Rejuvenate Bio’s treatment is a gene therapy that dials up expression of the genes sTGFbetaR2 and FGF21 to reduce levels of the cytokine TGF-beta1 and boost levels of the hormone FGF21, respectively. Both genes are associated with longevity.
“What we have seen from using a combination of two genes is the ability to affect multiple age-related diseases at once,” Oliver said.
Rejuvenate Bio published data in November 2019 showing that targeting these two genes in mice reduced kidney atrophy and reversed weight gain and Type 2 diabetes. The company had given extra copies of those genes, alone and in combination with each other and another gene called alpha-Klotho to see if they could boost the mice’s health and life spans. It found out that more isn’t necessarily better, as mice that were given all three genes together fared worse than the other animals did.
Someday, scientists believe, tiny DNA-based robots and other nanodevices will deliver medicine inside our bodies, detect the presence of deadly pathogens, and help manufacture increasingly smaller electronics.
Researchers took a big step toward that future by developing a new tool that can design much more complex DNA robots and nanodevices than were ever possible before in a fraction of the time.
In a paper published on April 19, 2021, in the journal Nature Materials, researchers from The Ohio State University – led by former engineering doctoral student Chao-Min Huang – unveiled new software they call MagicDNA.
If you want to own a piece of a longevity technology company, here is your chance.
Invest as little as $100 in startups and small businesses. Wefunder is the largest Regulation Crowdfunding portal.
Posted in biotech/medical, business, ethics, government, health, military, policy, robotics/AI | Leave a Comment on Dr. Hassan Tetteh, MD — Health Mission Chief — DoD/JAIC — The Art of Human Care For COVID-19
The Art Of Human Care For Covid-19 — Dr. Hassan A. Tetteh MD, Health Mission Chief, U.S. Department of Defense (DoD), Joint Artificial Intelligence Center, The Pentagon.
Dr. Hassan A. Tetteh, MD, is the Health Mission Chief, at the Department of Defense (DoD) Joint Artificial Intelligence Center, serving to advance the objectives of the DoD AI Strategy, and improve war fighter healthcare and readiness with artificial intelligence implementations.
Dr. Tetteh is also an Associate Professor of Surgery at the Uniformed Services University of the Health Sciences, adjunct faculty at Howard University College of Medicine, a Thoracic Staff Surgeon for MedStar Health and Walter Reed National Military Medical Center, and leads a Specialized Thoracic Adapted Recovery (STAR) Team, in Washington, DC, where his research in thoracic transplantation aims to expand heart and lung recovery and save lives.
In the past, Dr. Tetteh has served as Chief Medical Informatics Officer, United States Navy, and Division Lead for Futures and Innovation at Navy Medicine’s Headquarters, a Command Surgeon for the National Defense University, and as a Robert Wood Johnson Health Policy Fellow, assigned to the U.S. Congress, Congressional Budget Office, (CBO).
Dr. Tetteh served as Ship’s Surgeon and Director of Surgical Services for the USS Carl Vinson, deployed as a trauma surgeon to Afghanistan’s Helmand and Nimroz provinces, and has supported special joint forces missions to South America, the Middle East, the South Pacific, Australia, and Africa. He earned both the Surface Warfare Medical Department Officer and Fleet Marine Force Qualified Officer designations, and his military honors include two Meritorious Service Medals and the Joint Service Commendation Medal.
Dr. Tetteh is also an accomplished author, including the novel “Gifts of the Heart”, “Star Patrol” (co-authored with his son Edmund Tetteh), as well as “The Art of Human Care” and “The Art of Human Care for COVID-19″ (illustrated by his daughter Ella Bleue), and has published numerous articles on surgical innovation, health information technology, ethics, wounded warriors, and process improvement. He also serves on the board of directors for the Brooklyn, New York based Arthur Ashe Institute for Urban Health, Fayetteville, Arkansas based Champions for Kids, and Miriam’s Kitchen, a Washington, D.C. based nonprofit that works to end chronic homelessness.
Dr. Tetteh received his B.S. from State University of New York (SUNY), his M.D. from SUNY Downstate Medical Center, his M.P.A. from Harvard’s Kennedy School of Government, M.B.A. from Johns Hopkins University Carey Business School, and M.S. in National Security Strategy with a concentration in Artificial Intelligence from the National War College. He completed his thoracic surgery fellowship at the University of Minnesota and advanced cardiac surgery fellowship at Harvard Medical School’s Brigham and Women’s Hospital. Dr. Tetteh is a Certified Professional in Healthcare Information and Management, board certified in thoracic surgery, general surgery, clinical informatics, and healthcare management, and is a Fellow of the American College of Surgeons and Fellow of the American College of Healthcare Executives.
